Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

Dow Jones
2025/03/24
 

By Adria Calatayud and Helena Smolak

 

Bayer shares fell sharply after the company was ordered to pay $2.1 billion by a jury in a Georgia state court, the latest legal defeat for the company in a case about its Roundup weedkiller.

The German agricultural and pharmaceutical group said the jury in a trial in the State Court of Cobb County, Georgia, on Friday reached a verdict in favor of the plaintiff. The verdict includes $2 billion in punitive damages and $65 million in compensatory damages, the company said.

Shares in Bayer were down 6.6% at 22.48 euros in European morning trade Monday, having fallen as much as 8.8% earlier. The stock is up about 16% since the start of the year, amid a rally in German shares.

"We disagree with the jury's verdict, as it conflicts with the overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide," Bayer said. "We believe that we have strong arguments on appeal to get this verdict overturned and the excessive and unconstitutional damage awards eliminated or reduced."

The company said damages in cases that reached final judgments were reduced by 90% overall compared with the original jury awards.

The decision marks the latest legal setback for a company that has been fighting for years lawsuits stemming from its $63 billion acquisition of U.S. agrochemical firm Monsanto, which developed Roundup, closed in 2018. Critics have argued that glyphosate, the active ingredient found in Roundup, causes cancer though Bayer has long maintained that glyphosate is safe to use.

Bayer said it is currently evaluating the cases that would present the best opportunity to file a petition for review by the U.S. Supreme Court.

The company has so far paid around $10 billion to settle disputed claims, a spokesman said. Around 67,000 cases were still pending at the end of January and the company set aside $5.9 billion to cover glyphosate litigations, according to its annual report.

Bayer's chief executive, Bill Anderson, previously said that significantly containing litigation by the end of 2026 was one of his priorities.

 

Write to Adria Calatayud at adria.calatayud@wsj.com and to Helena Smolak

 

(END) Dow Jones Newswires

March 24, 2025 05:22 ET (09:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10